This report was first published by Endpoints News. To see the original version, click here
Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease.
The drugmaker said Thursday it will no longer develop two candidates, called JNJ-9530 and JNJ-4496. The former is a CD20-directed therapy, while the latter is a bispecific candidate that targets both CD20 and CD19. Both treatments are being tested in separate Phase 1 trials.
您已阅读22%（548字），剩余78%（1909字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。